This website is intended for residents of the U.S. interested in achondroplasia or VOXZOGO
Search

Here for you from the start

VOXZOGO is the first and only treatment FDA approved from birth for children with achondroplasia until growth plates close

Why VOXZOGO

Sophie, 9 months old, on VOXZOGO since 3 months old

Where would you like to begin?

Learn more about achondroplasia Get started with VOXZOGO Find resources and support

The impact of VOXZOGO

Witness how VOXZOGO® (vosoritide) helped to increase linear growth in children with achondroplasia.

View the Results

Annika, 6 years old, a child with achondroplasia before starting VOXZOGO treatment Annika, 14 years old, a teenager with achondroplasia who has experienced linear growth with VOXZOGO
Annika, 6 years old, a child with achondroplasia before starting VOXZOGO treatment Annika, 14 years old, a teenager with achondroplasia who has experienced linear growth with VOXZOGO

For illustrative purposes only, image scale is not matched.

Chosen by over 5,000 families across the world

Hear why thousands of families felt confident VOXZOGO was the right choice for their infants and children with achondroplasia.

Watch Their Stories

Collage of different VOXZOGO users
Collage of different VOXZOGO users

An established history in achondroplasia

FIRST & ONLY

treatment FDA
approved from birth

10+

years of clinical trial
experience in achondroplasia

5,000+

families have chosen
VOXZOGO worldwide

A commitment to the achondroplasia community

BioMarin has been dedicated to skeletal conditions for over 25 years—including 10+ years of clinical trial experience in achondroplasia. Whether you’re looking to connect with other caregivers for guidance, learn more about treatment by attending an educational event, or find specialized care near you, BioMarin is committed to providing resources to help the communities they serve continue to thrive.

VOXZOGO Mentor Program
Educational Events
Achondroplasia Doctor Finder

Widespread coverage to help get you started

Over 96%

of insured patients
have secured coverage
for VOXZOGO*

Over 96%

of eligible families with 
commercial insurance paid $0 out of pocket for VOXZOGO*†

Looking for more information about VOXZOGO?

Your local BioMarin representative can help you find answers.

Connect Now

*BioMarin RareConnections™ Data on file. Patients included are eligible VOXZOGO patients who have enrolled in BioMarin RareConnections and are on commercial therapy.
†With the BioMarin Co-Pay Assistance Program. Terms and Conditions apply. Valid only for patients with commercial prescription insurance coverage who have a valid prescription for an FDA-approved indication and who meet additional eligibility criteria. Not valid for prescriptions reimbursed, in whole or in part, by any federal, state, or government-funded insurance programs (for example, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD, or TRICARE) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any federal, state, or government-funded healthcare program, the patient will no longer be able to use the program and patient must notify BioMarin RareConnections at 1-866-906-6100 to stop participation. Patients residing in or receiving treatment in certain states may not be eligible for some or all of the program elements. Patients may not seek reimbursement for value received from the program from any third-party payers. Additional restrictions may apply. Offer subject to change or discontinuance without notice. This assistance offer is not health insurance. See BioMarin-copay-terms.com for full Terms and Conditions.

Connect With a Rep

IMPORTANT SAFETY INFORMATION

What is the most important safety information about VOXZOGO?

  • VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

What are the most common side effects of VOXZOGO?

  • The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

How is VOXZOGO taken?

  • VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.
  • Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.
  • The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.
  • Your healthcare provider will monitor the patient’s growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

What should you tell the doctor before or during taking VOXZOGO?

  • Tell your doctor about all of the patient’s medical conditions including
    • If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine).
    • If the patient has kidney problems or renal impairment.
    • If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby.
    • If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk.
  • Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional safety information in the full Prescribing Information and Patient Information.

What is VOXZOGO used for?

  • VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
  • VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.